In response to increasing pressure from Congress, the #FDA holds Friday hearing on the health effects of #CBD to determine a marketing path for CBD products. Learn more at https://nyti.ms/2KhMmqI
Research about the “entourage effect” of cannabinoids has led to potential treatments of neurodegenerative diseases such as Alzheimer’s Disease. For example, ingesting CBD along with THC not only dulls the intoxicating effects but can lead to a smoother effect rather than an experience of peaks and troughs. http://bit.ly/2W1zAPk
A UC Davis study has been testing the effectiveness of a synthetic CBD in treating seizures in rats, and found it to be as effective as the natural compound. In theory, artificially produced cannabinoids could offer great medical benefits, without the need to cultivate cannabis plants. BUT, some synthetics piercing the market are toxic, if not lethal. If the cannabis stigma, based on misinformed understanding, has been difficult to overcome for natural / non-synthetics options, considering the very real damage synthetics have caused, it seems doubtful that they will ever find a way into regular consumption. http://bit.ly/2W44XsQ
Piggybacking on the Juul craze, Hempods has created a #CBD distillate w/ other #cannabinoids and #terpenes. They also recognize the importance of third-party verification systems, like solosciences to inform and educate customers about their product http://bit.ly/2VUvJDT
Research on schizophrenia-affected rat models shows potential for #CBD to minimize many #schizophrenia symptoms
Cannabidiol (CBD) may have potential as a schizophrenia therapeutic agent. Individuals with schizophrenia exhibit decreased activity in choline acetyltransferase (ChAT) activity, an enzyme associated with cognitive functioning. In rat models mimicking schizophrenia, affected rats treated with CBD exhibited normal ChAt activity, while their untreated counterparts exhibited reduced activity.
CED Foundation Google Drive: http://bit.ly/2HHWW8E
Read Here or Download:
Cannabidiol (CBD) demonstrates a reduction in cue-induced heroin cravings and anxiety levels for those affected by heroin use disorder. In a study conducted at Mount Sinai hospital, former heroin abusers were treated with placebo, a low level of CBD, or a high level of CBD. Individuals who received either amount of CBD displayed fewer cravings in response to drug cues in the hours after administration, with those receiving the higher amount of CBD experiencing the lowest levels of craving one week after treatment. Participants treated with either amount of CBD exhibited significantly lower anxiety levels than the placebo group. CBD could be a viable treatment option for those suffering from heroin use disorder.
CED Foundation Google Drive: http://bit.ly/30AWkcH
Read Here or Download:
#CBD reduces anxiety levels not just in neurotypical users, but also with patients suffering from #FragileX
Individuals suffering from the neurodevelopmental disorder Fragile X Syndrome experience many symptoms mimicking those of autism, including increased anxiety. To investigate the effects of cannabidiol (CBD) on Fragile X symptom mitigation, a mouse model possessing the DNA mutations which give rise to Fragile X was treated with CBD. CBD treatment was shown to reduce anxiety in both affected and non-affected mice while preserving locomotive, social, and cognitive performance. Future studies exploring CBD as treatment for Fragile X may reveal other benefits.
Additional research may show potential for CBD as a therapeutic agent for hepatocellular carcinoma
Cannabinoid (CBD) may be an effective treatment for hepatocellular carcinoma (HCC). Cannabinoid receptor 2 (CB2 receptor) has demonstrated anti-tumor behavior in other tumor types. In a new study, HCC cells treated with MDA19, a molecule that binds to the CB2 receptor, grew more slowly than untreated cells. With CBD also binding to the CB2 receptor, there may be precedent for research on the potential of CBD as a treatment for HCC.
CED Foundation Google Drive: http://bit.ly/2YRTyhl
Read Here or Download:
Cannabis may be an effective treatment for Irritable Bowel Syndrome (IBS). cannabinoid receptor 2 (CB2), responsible for binding cannabidiol (CBD) and producing many of its known effects, can relieve many symptoms if IBS after activation by an “agonist” or binding partner. In rat models mimicking IBS, the presence of a CB2 receptor agonist decreased colonic hypermotility, a debilitating symptom of IBS. As CBD is an agonist of CB2, therapeutic innovations for IBS using cannabis may be possible.
CED Foundation Google Drive: http://bit.ly/2HHM8HF
Read Here or Download:
